BMS-backed Immatics' cell therapy shows early promise in small data set, prompting $110M offering

Bristol Myers Squibb-backed Immatics is wasting no time capitalizing on early phase 1a data that hints at promise or the company’s cell therapy ambitions, announcing a new public offering to raise $110 million.